Stockscreener 앱 받기
95.83
5.66%
-5.75
전일 마감가:
$101.58
열려 있는:
$102.68
하루 거래량:
1.13M
Relative Volume:
1.28
시가총액:
$2.69B
수익:
$267.23M
순이익/손실:
$-83.50M
주가수익비율:
-30.81
EPS:
-3.11
순현금흐름:
$-59.99M
1주 성능:
+25.51%
1개월 성능:
+28.87%
6개월 성능:
+177.77%
1년 성능:
+1,279%
1일 변동 폭
$90.26
$103.56
1주일 범위
$90.26
$115.60
52주 변동 폭
$6.79
$115.60
Genedx Holdings Corp Stock (WGS) Company Profile
명칭
Genedx Holdings Corp
전화
617 780 8742
주소
333 LUDLOW STREET, STAMFORD
WGS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
WGS
Genedx Holdings Corp
|
95.83 | 2.69B | 267.23M | -83.50M | -59.99M | -3.11 |
|
TMO
Thermo Fisher Scientific Inc
|
532.55 | 203.70B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
210.23 | 151.18B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
135.37 | 38.62B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IDXX
Idexx Laboratories Inc
|
452.77 | 37.07B | 3.90B | 887.87M | 808.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
191.04 | 33.64B | 15.41B | 1.37B | 2.11B | 7.50 |
Genedx Holdings Corp Stock (WGS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-28 | 개시 | Wells Fargo | Equal Weight |
| 2024-07-10 | 개시 | Craig Hallum | Buy |
| 2024-06-03 | 재개 | Jefferies | Hold |
Genedx Holdings Corp 주식(WGS)의 최신 뉴스
GeneDx Holdings Corp. (WGS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Markets Insider
Learn to Evaluate (WGS) using the Charts - Stock Traders Daily
The Goldman Sachs Group Forecasts Strong Price Appreciation for GeneDx (NASDAQ:WGS) Stock - Defense World
GeneDx (NASDAQ:WGS) Hits New 52-Week High on Better-Than-Expected Earnings - Armenian Reporter
Allspring Global Investments Holdings LLC Has $7.18 Million Position in GeneDx Holdings Corp. (NASDAQ:WGS) - Defense World
GeneDx Holdings Corp. SEC 10-K Report - TradingView
A Closer Look at GeneDx Hldgs's Options Market Dynamics - Benzinga
GeneDx Holdings Corp.: A Comprehensive Analysis - HPBL
Bronstein, Gewirtz & Grossman, LLC Is Investigating GeneDx Holdings Corp. (WGS) And Encourages Investors to Connect - Markets Insider
Reviewing GeneDx Holdings: Exome Testing And EPIC Aura Integration Make It A GARP 'Buy' - Seeking Alpha
GeneDx Holdings Corp. (NASDAQ:WGS) Q4 2024 Earnings Call Transcript - Insider Monkey
GeneDx price target raised to $135 from $118 at TD Cowen - TipRanks
3 Stocks On US Exchange Estimated To Be Undervalued By Up To 36.2% - Simply Wall St
GeneDx Holdings Corp (WGS) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ... By GuruFocus - Investing.com Canada
GeneDx (NASDAQ:WGS) Hits New 52-Week High After Better-Than-Expected Earnings - Defense World
GeneDx Reports Strong 2024 Growth and 2025 Outlook - TipRanks
GeneDx Highlights Strong Growth in Earnings Call - TipRanks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp.WGS - PR Newswire
GeneDx Stock Was up 2,700% in 2024 — Can It Keep Rising? - Investing.com
GeneDx Holdings Corp: A Stock on the Rise - RagingBull
Craig Hallum Raises GeneDx Holdings' Price Target to $114 From $95, Keeps Buy Rating - Marketscreener.com
Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday - Benzinga
GeneDx targets $350M-$360M revenue for 2025 with 30% growth in exome and genome testing - MSN
Earnings call transcript: GeneDx Q4 2024 beats forecasts, stock surges - Investing.com
GeneDx Holdings earnings beat by $0.56, revenue topped estimates - Investing.com
GeneDx Holdings Corp. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
GeneDx Holdings Corp. (WGS) Q4 Earnings and Revenues Surpass Estimates - Yahoo Finance
GeneDx Swings to Adjusted Net Income, Revenue Rises; 2025 Revenue Guidance Set - Marketscreener.com
GeneDx Holdings Corp. Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025 - BioSpace
Genedx Holdings Corp FY 2025 Revenue Guidance Of $350M To $360M -February 18, 2025 at 06:20 am EST - Marketscreener.com
GeneDx Holdings Corp. Provides Earnings Guidance for the Full Year of 2025 -February 18, 2025 at 06:00 am EST - Marketscreener.com
GeneDx Holdings Corp. (NASDAQ:WGS) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against GeneDx Holdings Corp. (WGS) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
GeneDx Holdings Corp. (WGS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Markets Insider
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio? - Benzinga
GeneDx (WGS) Projected to Post Earnings on Tuesday - Defense World
GeneDx (WGS) Expected to Announce Earnings on Tuesday - MarketBeat
GeneDx (NASDAQ:WGS) Shares Up 8%Should You Buy? - MarketBeat
Legato Capital Management LLC Has $2.13 Million Stake in GeneDx Holdings Corp. (NASDAQ:WGS) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against GeneDx Holdings Corp. (WGS) And Encourages Stockholders to Reach Out - Markets Insider
GeneDx launches ultrarapid whole genome sequencing for critically ill infants - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating GeneDx Holdings Corp. (WGS) And Encourages Stockholders to Connect - Markets Insider
GeneDx speeds up genome sequencing for NICU care By Investing.com - Investing.com South Africa
GeneDx Announces ultraRapid Whole Genome Sequencing, Delivering Actionable Results in as soon as 48 Hours to Inform Care for Critically Ill NICU and PICU Patients - Business Wire
GeneDx (NASDAQ:WGS) Shares Down 6.7%Should You Sell? - MarketBeat
GeneDx to Participate in 45th Annual TD Cowen Health Care Conference - Business Wire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against GeneDx Holdings Corp. (WGS) and Encourages Stockholders to Learn More About the Investigation - Markets Insider
GeneDx (NASDAQ:WGS) Stock Price Down 6.7%What's Next? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages GeneDx Holdings Corp. (WGS) Investors to Inquire about Securities Investigation - Markets Insider
Closing Strong: GeneDx Holdings Corp (WGS) Ends at 59.54, Down -4.23 from Last Close - The Dwinnex
Genedx Holdings Corp (WGS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Genedx Holdings Corp 주식 (WGS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Jan 29 '25 |
Option Exercise |
0.00 |
753 |
0 |
3,225 |
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Jan 29 '25 |
Sale |
78.48 |
275 |
21,582 |
2,950 |
| Stueland Katherine | Chief Executive Officer |
Jan 29 '25 |
Option Exercise |
0.00 |
3,874 |
0 |
5,594 |
| Stueland Katherine | Chief Executive Officer |
Jan 29 '25 |
Sale |
78.48 |
1,657 |
130,046 |
3,937 |
0.06%
3.50%
자본화:
|
볼륨(24시간):